In this Paper Summary we discuss:
More about this Paper Summary
Adoptive cell transfer (ACT) is a promising therapeutic approach in the fight against cancer.
Conventionally in this therapy, patients receive tumor-infiltrating lymphocytes (TILs) or T cell receptor (TCR)-engineered blood T cells, along with high doses of interleukin-2 (IL-2) to support the expansion and function of the transferred cells.
However, IL-2-induced toxicity and immunosuppression pose problems for patients, limiting the clinical use of ACT. Parisi et al. utilized IsoPlexis’ functional proteomics-based cellular characterization to overcome these challenges.
Download this Paper Summary to learn more!